Teva Pharmaceutical Industries’ new chief executive is set to shift the company’s focus to branded drugs from generics as he imports a successful strategy of making mid-sized deals from Bristol-Myers Squibb. The transformation -- which hinges on Jeremy Levin picking a handful of winning new products to boost Teva’s branded portfolio -- is unlikely to happen overnight. In hunting for potentially lucrative experimental medicines, Levin will be competing with a wide field of rivals, including the world’s biggest pharmaceutical manufacturers, most of whom are hungry for new drugs to refill pipelines depleted by patent expirations.
